Cargando…

Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?

BACKGROUND: Advanced pancreatic cancer (APC) patients often have substantial symptom burden. In Ontario, patients routinely complete the Edmonton Symptom Assessment Scale (ESAS), which screens for nine symptoms (scale: 0‐10), in cancer clinics. We explored the association between baseline patient‐re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Wei Fang, Beca, Jaclyn, Guo, Helen, Isaranawatchai, Wanrudee, Schwartz, Deborah, Naipaul, Rohini, Arias, Jessica, Qiao, Yao, Gavura, Scott, Redmond‐Misner, Ruby, Ismail, Zahra, Barbera, Lisa, Chan, Kelvin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943146/ https://www.ncbi.nlm.nih.gov/pubmed/31736256 http://dx.doi.org/10.1002/cam4.2704

Ejemplares similares

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
por: Chan, Kelvin K. W., et al.
Publicado: (2019)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario
por: Naipaul, Rohini D., et al.
Publicado: (2021)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
por: Raphael, Michael J., et al.
Publicado: (2021)

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2022)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Oral hygiene and the overall survival of head and neck cancer patients
por: Chang, Chan‐Chi, et al.
Publicado: (2019)

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
por: Parmar, Ambica, et al.
Publicado: (2023)

Racial disparities in overall survival among renal cell carcinoma patients with young age and small tumors
por: Schwartz, Kendra, et al.
Publicado: (2015)

Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma
por: Zhou, Xiaohan, et al.
Publicado: (2021)

Cost‐effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person‐level data in a Canadian setting
por: Thein, Hla‐Hla, et al.
Publicado: (2017)

Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer
por: Wang, Qing, et al.
Publicado: (2021)

High impact of macroaggregated albumin‐based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90)Y‐loaded glass microsphere radioembolization
por: Garin, Etienne, et al.
Publicado: (2016)

The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis
por: Barbera, Lisa, et al.
Publicado: (2020)

Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes
por: Xu, Amy J., et al.
Publicado: (2019)

Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
por: Ter‐Minassian, Monica, et al.
Publicado: (2017)

A hypoxia-related prognostic model predicts overall survival and treatment response in hepatocellular carcinoma
por: Xing, Jiyuan, et al.
Publicado: (2022)

Economic evaluation of smoking cessation in Ontario's regional cancer programs
por: Djalalov, Sandjar, et al.
Publicado: (2018)

Uronic acid metabolic process–related gene expression–based signature predicts overall survival of glioma
por: Feng, Yuemei, et al.
Publicado: (2021)

Establishment of a nine‐gene prognostic model for predicting overall survival of patients with endometrial carcinoma
por: Ying, Jianchao, et al.
Publicado: (2018)

Improving the overall survival prognosis prediction accuracy: A 9‐gene signature in CRC patients
por: Zheng, Wenbo, et al.
Publicado: (2021)

Signature based on metabolic‐related gene pairs can predict overall survival of osteosarcoma patients
por: Li, Long‐Qing, et al.
Publicado: (2021)

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Association of radiation dose intensity with overall survival in patients with distant metastases
por: Kao, Johnny, et al.
Publicado: (2021)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
por: Best, Till Dominik, et al.
Publicado: (2021)

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer
por: Lee, Shu‐Hui, et al.
Publicado: (2019)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Overweight and obesity predict better overall survival rates in cancer patients with distant metastases
por: Tsang, Ngan Ming, et al.
Publicado: (2016)

The prediction models for postoperative overall survival and disease‐free survival in patients with breast cancer
por: Shigemizu, Daichi, et al.
Publicado: (2017)

Prognostic nomograms to predict overall survival and cancer‐specific survival in patients with pelvic chondrosarcoma
por: Chen, Li, et al.
Publicado: (2019)

Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer
por: Diao, Jian‐dong, et al.
Publicado: (2019)

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
por: Watts, Eleanor L, et al.
Publicado: (2022)

Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients
por: Li, Shunrong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ang6ev6pk1k08b0bheltgdjjbh